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In 2012, the Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines have been released and detailed 
and graded recommendations concerning all the aspects 
of critical care nephrology (1). One of the chapters is 
specifically dedicated to “Dialysis Interventions for 
Treatment of acute kidney injury (AKI); Timing of renal 
replacement therapy (RRT)”. Even if the question on when 
to start RRT is constantly solicited by nephrologists and 
intensivists in case of severe AKI (2), KDIGO guidelines 
only provided expert opinion statements: “Initiate RRT 
emergently when life-threatening changes in fluid, electrolyte, 
and acid-base balance exist (Not Graded)” and “Consider the 
broader clinical context, the presence of conditions that can be 
modified with RRT, and trends of laboratory tests—rather than 
single BUN and creatinine thresholds alone—when making 
the decision to start RRT (Not Graded)” (1). In current 
clinical practice, the decision to start RRT is based on 
the development of volume overload, not responding to 
diuretics, and biochemical features of solute imbalance 
(azotemia, hyperkalemia, severe acidosis): these indications 
may lead the physicians to avoid dialysis as long as possible 
with the aim of giving time to spontaneous recovery of renal 
function and of avoiding the risks associated with RRT (1), 
including chronic renal dysfunction (3). On the other side, 
promoters of anticipated RRT start may be indicating 
dialysis in patients who would not have needed it. Given 
this range of uncertainty, a single-center randomized trial, 
specifically designed to evaluate early initiation of RRT in 
critically ill patients with AKI, has been recently published 
in the Journal of American Medical Association (JAMA) 
by Zarbock and co-workers (4): the Early or deLAyed 
Initiation of RRT (ELAIN) trial. This study showed that 
90-day all-cause mortality is significantly reduced by early 
RRT start. Interestingly, another similar (early vs. delayed 
RRT strategy) bigger multi-center randomized trial, by 
Gaudry et al. on the New England Journal of Medicine (NEJM) 
failed to reach the benefit in overall survival at day 60 as 
primary outcome (5): the Artificial Kidney Initiation in 
Kidney Injury (AKIKI) trial. Due to the different results, 
the two studies have to be critically analyzed before 
reaching any final conclusion. The aim of the present 
editorial is to analyze the main differences, strengths and 
limitations of the two studies and to finally summarize some 
critical conclusions.
AKI severity (stage) at randomization represents the 
most evident difference between ELAIN and AKIKI. 
KDIGO stage 2 is reached when serum creatinine increases 
2.0–2.9 times baseline level or urine output (UO) decreases 
below 0.5 mL/kg/h for 12 hours, while KDIGO stage 3 
is reached when serum creatinine increases 3.0 times the 
baseline level or above 4.0 mg/dL or UO decrease below 
0.3 mL/kg/h for 24 hours or anuria is present for 
≥12 hours. In the JAMA study, indications to start RRT were: 
KDIGO stage 2; plasma neutrophil gelatinase-associated 
lipocalin (NGAL) >150 ng/mL; one of the following: severe 
sepsis, use of vasopressors or catecholamines, refractory 
fluid overload, development or progression of non-renal 
organ dysfunction [Sequential Organ Failure Assessment 
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(SOFA) score ≥2]. In the NEJM study, the patients had to 
reach the stage 3 criteria to be enrolled in the trial (Table S1). 
Therefore, at first sight, when the two studies are compared 
it is clear that the level of renal severity was significantly 
different. According to this consideration, Gaudry et al., 
when listing the limitations of the study, clearly underlined 
that the AKI severity of enrolled patients was advanced and, 
therefore, the observed results may not be generalizable to 
patients with lower KDIGO stages.
Second, substantial differences in “early” and “delayed” 
definitions differentiate the two studies (Table S1). The 
“early” arm in the JAMA study was composed by patients 
treated by RRT within 8 hours from stage 2 AKI while in 
the NEJM treatment was delivered as soon as the patient 
reached a stage 3 AKI plus need of mechanical ventilation 
(MV), or catecholamines, or both. The “delayed” group 
in the JAMA study implied RRT start within 12 hours of 
diagnosis of stage 3 or any of the following: serum urea level 
higher >100 mg/dL; hyperkalemia (>6 mEq/L) and/or with 
electrocardiography abnormalities; serum magnesium level 
>8 mEq/L; UO <200 mL/12 hours or anuria; and organ 
edema in the presence of AKI resistant to diuretic treatment 
(one attempt with loop diuretics prior to randomization). 
In the NEJM study “delayed” patients started RRT when 
one of the following conditions was reached: severe 
hyperkalemia, metabolic acidosis, pulmonary edema, 
BUN >112 mg/dL, anuria or oliguria >72 hours after 
randomization. These different definitions of “early” and 
“delayed” timing and, therefore, in clinical severity, need 
a further comment: it is possible that early patients of the 
ELAIN trial were the less severe ones and it is probably not 
surprising that their outcomes were significantly improved. 
At the bedside, it is unlikely that a KDIGO stage 2 patient, 
outside a rigid randomization protocol, would be ever 
considered for RRT. 
Another key point that deserves a comment is that more 
than 50% of the patients in the NEJM study received 
intermittent hemodialysis (IHD) as the first method 
of therapy and only 30% of them received continuous 
renal-replacement therapy (CRRT) as the sole method 
(with no intermittent dialysis at any time). In respect 
of this point, the KDIGO guidelines (1) suggest to “use 
continuous and intermittent RRT as complementary therapies 
in AKI patients. (Not graded)” but “suggest using CRRT, 
rather than standard intermittent RRT, for hemodynamically 
unstable patients (2B)”. In light of this aspect and taking 
into consideration that in the NEJM study vasopressor 
support with epinephrine or norepinephrine was necessary 
in 85% of both groups, such a wide application of IHD 
might imply some concerns on patients’ outcomes. It must 
be acknowledged, however, that centers routinely applying 
IHD to critically ill patients are generally able to manage 
those with hemodynamic instability. Still, generalizability 
of AKIKI trial results might be argued in those centers only 
applying CRRT. Much differently in the Zarbock et al.’s 
study all the patients were exclusively treated with CRRT 
with a precise treatment protocol (predilution; dialysate 
to replacement fluid =1:1; dose 30 mL/kg/h, blood flow 
>110 mL/min, citrate for anticoagulation). The application 
of a precise and homogenous protocol is a consistent 
strength that should be considered: this is likely due to the 
fact that a single-center study does not have to take into 
consideration multiple institutions’ choices and preferences. 
However, in the AKIKI trial RRT prescription was not pre-
specified and the role of RRT dose in affecting outcomes of 
early and delayed treatments remains unsolved.
A huge difference between the studies is also represented 
by the primary outcome: in a total of 231 patients the 
Zarbock et al.’s study showed an overall mortality at 90-day 
follow-up of 39.3% (44/112) in the early group and 54.7% 
(65/119) in the delayed group (P=0.03; between-group 
difference, −15.4%). Differently, in the Gaudry et al.’s 
study an early RRT failed to demonstrate any benefit 
of early vs. delayed strategy since the 60-days mortality 
rate was 58.5% in the early group and 49.7% in the 
delayed group (P=0.79) (Table S1). Noteworthy, most of 
the secondary outcomes were reached in Zarbock et al.’s 
study further suggesting the advantages of starting RRT 
early (e.g., duration of RRT, recovery of renal function, 
duration of mechanical ventilation, length of hospital and 
intensive care unit (ICU) stay, requirement of RRT at 
day 90, decrease in IL-6 and IL-8 plasma concentration) 
(Table S1). Similarly to the primary outcome, the main 
secondary outcomes were not reached in the Gaudry 
et al.’s study and, in addition, bloodstream catheter infection 
and hypophosphatemia resulted worst in the early group 
(P=0.03 for both). Interestingly, in the AKIKI trial, 49% 
of patients enrolled in the delayed arm did not receive 
any RRT (compared to 9% in the ELAIN). Moreover, 
it should be underlined that, in Gaudry et al.’s study, the 
lowest mortality at day 60 (37.1%) was found among 
patients who never received RRT, and the highest mortality 
(61.8%) was found among those who received therapy late, 
whereas intermediate mortality (48.5%) was found among 
patients who received therapy early (P<0.001). Patients 
in the delayed-strategy group who never received dialysis 
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were less ill at baseline, and patients who received it late 
were the most severely ill patients at baseline. Moreover, 
the differences in mortality became nonsignificant after 
adjustment for baseline severity of illness. These aspects 
strongly suggest the importance of RRT timing with 
respect to severity of illness: if it is might be true that in the 
“average” patient the effect of RRT timing in mortality is 
diluted, it is also true that the “average” patient does not 
exist in the real world. It is certain that the most severely 
critically ill patients have to be aggressively and timely 
treated in order to attempt a change of their clinical history.
Discontinuation strategy is another key aspect in 
the management of patients treated with RRT. Current 
literature is quite blurred also in this field of acute RRT. 
KDIGO guidelines’ criteria (1) for stopping RRT in AKI 
state: “Discontinue RRT when it is no longer required, either 
because intrinsic kidney function has recovered to the point that 
it is adequate to meet patient needs, or because RRT is no longer 
consistent with the goals of care. (Not Graded)” and “We suggest 
not using diuretics to enhance kidney function recovery, or to 
reduce the duration or frequency of RRT (2B)”. Discontinuation 
strategy also slightly differed in Gaudry et al.’s and Zarbock 
e t  a l . ’s  s tudies :  in  the f i rs t  one,  in  both groups , 
discontinuation of RRT was considered if the spontaneous 
UO was >500 mL/24 hours and it was highly recommended 
if the spontaneous UO was higher than 1,000 mL per 
24 hours in the absence of diuretic therapy or if UO was 
>2,000 mL per 24 hours in patients who were receiving 
diuretic therapy and mandatory if diuresis was sufficient 
to allow for spontaneous decrease in serum creatinine 
concentration. In Zarbock et al.’s study, renal recovery 
was defined by UO >400 mL/24 hours without and 
2,100 mL/24 hours with diuretic treatment and creatinine 
clearance >20 mL/min. The ideal threshold for RRT 
discontinuation is clearly a fundamental aspect for 
evaluation of therapy efficacy.
Based on the observed results, the first novel element 
we should appreciate is that both studies feasibly and quite 
easily achieved the “early RRT”: it is currently possible to 
anticipate RRT, if indicated. Then it could be hypothesized 
that early initiation of RRT may lead to clinical benefits by 
quickly controlling the metabolic or uremic derangements, 
by preventing the deleterious effects of fluid overload 
and by attenuating kidney-specific and non-kidney organ 
injury (e.g., inflammatory damage). According to Zarbock 
et al., using a combination of the KDIGO classification 
system and the plasma NGAL concentration may be of 
help in detecting those patients that most probably benefit 
from early RRT. On the other side, even if Gaudry et al.’s 
conclusions were against the benefit of early RRT initiation 
and that the recovery of renal function (identified by 
diuresis), was more rapid in the delayed-strategy group than 
in the early-strategy group, the authors cleverly concluded 
that their study suggests a careful surveillance of each case 
to decide when RRT should be started with a benefit-to-
risk ratio approach. 
It is our personal consideration that, although both 
studies have been conducted on a large population of 
patients, with high level scientific methodology and 
with rigorous study designs, the significant differences 
in the various characteristics of the two studies suggest 
great attention before reaching any conclusion about 
early or late RRT benefits in patients with AKI. Patients 
with AKI, admitted or not to the ICU, clearly have very 
different origins of kidney damage with variable degrees 
of organs involvement with a variable degrees of severity: 
some have multiorgan failure with underlying severe 
coexisting comorbidities and they might have significantly 
different clinical courses from post-surgical patients with 
AKI or isolated organ dysfunction. Careful stratification 
based on organ dysfunction, main acute disease, chronic 
comorbidities, medications, nutritional needs, and fluid 
status could better select the right patient, the right 
time, the right method and, more completely, the right 
therapeutic bundle. Moreover, the attempt to standardize 
the timing for RRT into early and delayed, without 
evaluating each patient with a “holistic” view may expose the 
patient to both risks of a delayed and an early strategy: in 
one case being too late and in the other being useless. Great 
attention, furthermore, should be payed to patients who 
would recover renal function with conservative treatment 
alone because those have probably a high chance of good 
outcome. In conclusion, rather than trying to aprioristically 
deliver RRT soon or late on the basis of limited scoring 
systems, it would be better to personalize this vital therapy 
not differently from all the other therapies commonly 
administered in critically ill patients with organ failure. 
These considerations are in agreement with an interesting 
contribution by Mehta who commented Gaudry et al.’s 
study underlining the “need for dynamic risk-stratification 
tools to identify patients who will not need renal-replacement 
therapy for management of their acute kidney injury” and 
that “meanwhile, we should focus on the timely application of 
renal-replacement therapy while considering individual patient 
characteristics, process-of-care elements, and logistics to achieve 
therapeutic goals” (6). It is our personal expectation that 
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further stratification by novel biomarkers and further in 
depth analysis of patients genotypes might help clinicians in 
correct therapeutic identification (7,8). As a final thought, 
however, we would like to remark that, so far, our everyday 
challenge remains a “phenotypic” and imprecise clinical 
evaluation, as important and careful, though, as it represents 
the cornerstone of patients’ survival. It is possible that the 
Standard vs. Accelerated Initiation of RRT in Acute Kidney 
Injury (STARRT-AKI) multicenter trial (NCT02568722), 
currently recruiting patients (up to a target of about 3,000), 
will provide us with some more (definitive) iron in the fire.
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Table S1 Comparison of Zarbock et al.’s and Gaudry et al.’s study 
Zarbock et al. (JAMA) Gaudry et al. (NEJM)
Primary outcome 90-day all-cause mortality Survival at day 60
Secondary outcomes 28- and 60-day mortality, clinical evidence of organ dysfunction, recovery of 
renal function, requirement of RRT after day 90, duration of renal support, 
ICU and hospital LoS, and markers of inflammation [IL-6, IL-8, IL-10, IL-18, 
and macrophage migration inhibitory factor (MIF)]
Receipt of RRT at least once with the delayed strategy; the numbers of RRT-free days, dialysis 
catheter-free days, MV-free days, and vasopressor therapy-free days SOFA score at day 3 and day 
7; the vital status at day 28; the LoS in the ICU and in the hospital; the proportion of patients with 
treatment limitations (i.e., withholding or withdrawal of treatment); the occurrence of nosocomial 
infections; and complications potentially related to AKI or RRT
Design Single-center (University hospital in Germany) randomized clinical trial—
August 2013–June 2015 
Unblinded, multicenter (31 ICUs in France), randomized trial—September 2013–January 2016 
Setting Early: within 8 hours of diagnosis of KDIGO stage 2 Early: immediately after randomization (KDIGO stage 3+ MV, or catecholamines, or both)*
Participants Delayed: within 12 hours of diagnosis of KDIGO stage 3 or no initiation Delayed: if one of the following:
(I) severe hyperkalemia
(II) metabolic acidosis
(III) pulmonary edema
(IV) BUN >112 mg/dL
(V) Anuria or oliguria >72 hours after randomization
Results Patients Patients
Total: 231 Total: 619
Early: 112 Early: 311
Delayed: 119 Delayed: 308
Received RRT** Received RRT**
Early: 112 (100%) Early: 305 (98%)
Delayed: 108 (91%) Delayed: 157 (51%)
Timing (RRT start) Timing (RRT start)
Early: 6.0 hours (Q1, Q3: 4.0, 7.0) Early: median of 2.0 hours (IQR, 1–3)
Delayed: 25.5 hours (Q1, Q3: 18.8, 40.3) Delayed: median 57 hours (IQR, 25–83)
Primary outcome Primary outcome
Mortality 90 days Mortality 90 days
Early: 39.3%; Early: 58.5%
Delayed:54.7%; Delayed: 49.7%
P=0.03 P=0.79
Secondary outcomes Secondary outcomes
Duration of RRT
(I) Early: 9 days (Q1, Q3: 4, 44) for the early group;
(II) Delayed: 25 days (Q1, Q3: 7, >90);
(III) P=0.04;
(IV) Between-group difference, −18
In the delayed-strategy group, 61% of the 155 who were alive at day 60 had not received RRT
Dependence on RRT at day 28
(I) Early: 12%;
(II) Delayed: 10%;
(III) P=0.51
Enhanced recovery of renal function at day 90
(I) Early: 53.6%;
(II) Delayed: 38.7%;
(III) P=0.02
(IV) Between-group difference, 14.9%
Dependence on RRT at day 60
(I) Early: 12%
(II) Delayed: 10%
(III) P=0.12
Catheter-related bloodstream infections
(I) Early: 10%
(II) Delayed: 5%
(III) P=0.03
MV
(I) Early: 125.5 hours (Q1, Q3: 41, 203);
(II) Delayed: 81.0 days (Q1, Q3: 65, 413);
(III) P=0.002;
(IV) Between-group difference, −60 hours
Hypophosphatemia:
(I) Early: 22%;
(II) Delayed: 15%;
(III) P=0.03
LoS (hospital)
(I) Early: 51 days (Q1, Q3: 31, 74);
(II) Delayed 82 days (Q1, Q3: 67, >90) for the delayed group;
(III) P<0.001
LoS (ICU)
(I) Early: 19 days (Q1, Q3: 9, 29);
(II) Delayed: 22 days (Q1, Q3: 12, 36) in the delayed group;
(III) P=0.33;
(IV) Between-group difference, −3.0
Requirement of RRT on day 90
(I) Early: 13.4%;
(II) Delayed: 15.1%;
(III) P=0.80
CK (IL-6)
(I) Early: 399.4 pg/mL;
(II) Delayed: 989.3 pg/mL;
(III) P=0.02
CK (IL-8)
(I) Early: 65.7 pg/mL;
(II) Delayed: 215.5 pg/mL;
(III) P=0.001
MIF, IL-10, and IL-18 did not differ between groups
Other secondary outcomes did not differ significantly between the two study groups; adequate 
diuresis together with no need for RRT were observed earlier in the delayed-strategy group than in 
the early strategy group (P<0.001)
Conclusions Among critically ill patients with AKI, early RRT compared with delayed 
initiation of RRT reduced mortality over the first 90 days
No significant difference with regard to mortality between an early and a delayed strategy for the 
initiation of RRT. A delayed strategy averted the need for RRT in an appreciable number of patients
*, without life-threatening conditions related to renal failure. AKI compatible with a diagnosis of acute tubular necrosis in the context of ischemic or toxic injury; **, the choice of the method of renal replacement 
therapy was left to the discretion of each study site; RRT, renal replacement therapy; LoS, length of stay; IL, interleukin; ICU, intensive care unit; AKI, acute kidney injury; MV, mechanical ventilation; SOFA, 
Sequential Organ Failure Assessment; KDIGO, Kidney Disease Improving Global Outcomes; Q, quartile; IQR, interquartile range.
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